(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion - 2The most effective method to Augment Benefits in Gold Speculation: Systems and Tips
- 3I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- 4The breakout star of NASA's Artemis 2 moon mission isn't an astronaut — it's the space toilet
- 56 Famous kind of practice on the planet
- Slims down for Maintainable Weight reduction
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Looking for under-the-radar adventures? Try Norway's Vesterålen
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
- Reconnecting with an old friend is a story of distance, loss and rediscovery
- Effectiveness Uncovered: A Survey of \Smoothing out Your Errands\ Efficiency Application
- Partner of crime boss Steven Lyons arrested in Dubai
- UK consumer confidence plunges amid escalating Iran conflict
- Washington resident is infected with a different type of bird flu
